Production (Stage)
Xenon Pharmaceuticals Inc.
XENE
$29.75
-$0.74-2.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 38.31% | 44.79% | 32.86% | 12.86% | 11.98% |
| Gross Profit | -21.36% | -44.79% | -32.86% | -12.86% | -11.98% |
| SG&A Expenses | 28.71% | 42.68% | 30.47% | 67.49% | 55.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.90% | 44.29% | 32.31% | 24.23% | 20.37% |
| Operating Income | -23.20% | -44.29% | -32.31% | -24.23% | -20.37% |
| Income Before Tax | -35.99% | -54.70% | -29.81% | -22.18% | -14.68% |
| Income Tax Expenses | 3.64% | -1,777.07% | -103.82% | -51.36% | 42.07% |
| Earnings from Continuing Operations | -35.71% | -46.81% | -29.57% | -22.05% | -14.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.71% | -46.81% | -29.57% | -22.05% | -14.87% |
| EBIT | -23.20% | -44.29% | -32.31% | -24.23% | -20.37% |
| EBITDA | -23.31% | -45.42% | -35.32% | -24.40% | -20.04% |
| EPS Basic | -33.82% | -31.04% | -9.75% | -3.50% | 2.71% |
| Normalized Basic EPS | -34.09% | -37.64% | -8.86% | -1.41% | 7.06% |
| EPS Diluted | -33.82% | -31.04% | -9.75% | -3.50% | 2.71% |
| Normalized Diluted EPS | -34.09% | -37.64% | -8.86% | -1.41% | 7.06% |
| Average Basic Shares Outstanding | 1.41% | 12.03% | 18.07% | 17.93% | 18.06% |
| Average Diluted Shares Outstanding | 1.41% | 12.03% | 18.07% | 17.93% | 18.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |